JP6472454B2 - 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物 - Google Patents
炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物 Download PDFInfo
- Publication number
- JP6472454B2 JP6472454B2 JP2016548110A JP2016548110A JP6472454B2 JP 6472454 B2 JP6472454 B2 JP 6472454B2 JP 2016548110 A JP2016548110 A JP 2016548110A JP 2016548110 A JP2016548110 A JP 2016548110A JP 6472454 B2 JP6472454 B2 JP 6472454B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mixture
- compounds
- disease
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC=N[C@]1C(NI*)=CC(I)=CC1N* Chemical compound CC=N[C@]1C(NI*)=CC(I)=CC1N* 0.000 description 25
- XYGHIBKTXMTRME-UHFFFAOYSA-N CCc(cc(C#N)nc1)c1N(C)c1cc(N)c2nc(C[N]#Cc(cc3CC)ncc3N(C)c3cc(NC(OC)=O)c4nc[n](C)c4c3)[n](C)c2c1 Chemical compound CCc(cc(C#N)nc1)c1N(C)c1cc(N)c2nc(C[N]#Cc(cc3CC)ncc3N(C)c3cc(NC(OC)=O)c4nc[n](C)c4c3)[n](C)c2c1 XYGHIBKTXMTRME-UHFFFAOYSA-N 0.000 description 1
- OEHLVXUBESOUTE-UHFFFAOYSA-N CN(c1ccc2nc[n](C)c2c1)c(ccc(C#N)c1)c1F Chemical compound CN(c1ccc2nc[n](C)c2c1)c(ccc(C#N)c1)c1F OEHLVXUBESOUTE-UHFFFAOYSA-N 0.000 description 1
- QDXJAGXUNYFXRG-UHFFFAOYSA-N C[n]1c(cc(cc2)Br)c2nc1 Chemical compound C[n]1c(cc(cc2)Br)c2nc1 QDXJAGXUNYFXRG-UHFFFAOYSA-N 0.000 description 1
- MTIVXWHSWKXOJZ-UHFFFAOYSA-N Cc(cc1NC)cc2c1nc[n]2C Chemical compound Cc(cc1NC)cc2c1nc[n]2C MTIVXWHSWKXOJZ-UHFFFAOYSA-N 0.000 description 1
- SXXPXZVLNNYFEZ-UHFFFAOYSA-N Cc1cc(C#N)ncc1Oc1cc(N)c2nc[n](C)c2c1 Chemical compound Cc1cc(C#N)ncc1Oc1cc(N)c2nc[n](C)c2c1 SXXPXZVLNNYFEZ-UHFFFAOYSA-N 0.000 description 1
- NCYZHYJKFREHQV-UONOGXRCSA-N Cc1cc(C#N)ncc1Oc1cc(NC([C@@H](C2)[C@@H]2F)=O)c2nc[n](C)c2c1 Chemical compound Cc1cc(C#N)ncc1Oc1cc(NC([C@@H](C2)[C@@H]2F)=O)c2nc[n](C)c2c1 NCYZHYJKFREHQV-UONOGXRCSA-N 0.000 description 1
- JZARETXQTGGESS-UHFFFAOYSA-N Cc1cc(N)c2nc[n](C)c2c1 Chemical compound Cc1cc(N)c2nc[n](C)c2c1 JZARETXQTGGESS-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N c1cc2nccnc2cc1 Chemical compound c1cc2nccnc2cc1 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1ccnnc1 Chemical compound c1ccnnc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N c1cncnc1 Chemical compound c1cncnc1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N c1nccnc1 Chemical compound c1nccnc1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1401086.2 | 2014-01-23 | ||
| GBGB1401086.2A GB201401086D0 (en) | 2014-01-23 | 2014-01-23 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2015/050850 WO2015110378A1 (en) | 2014-01-23 | 2015-01-19 | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503834A JP2017503834A (ja) | 2017-02-02 |
| JP2017503834A5 JP2017503834A5 (enExample) | 2018-02-22 |
| JP6472454B2 true JP6472454B2 (ja) | 2019-02-20 |
Family
ID=50287405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548110A Active JP6472454B2 (ja) | 2014-01-23 | 2015-01-19 | 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9440929B2 (enExample) |
| EP (2) | EP3395802A1 (enExample) |
| JP (1) | JP6472454B2 (enExample) |
| CN (1) | CN106132934B (enExample) |
| AR (1) | AR099160A1 (enExample) |
| AU (1) | AU2015208269B2 (enExample) |
| BR (1) | BR112016016732B1 (enExample) |
| CA (1) | CA2941474A1 (enExample) |
| CY (1) | CY1120679T1 (enExample) |
| DK (1) | DK3097083T3 (enExample) |
| EA (1) | EA029827B1 (enExample) |
| ES (1) | ES2693019T3 (enExample) |
| GB (1) | GB201401086D0 (enExample) |
| HR (1) | HRP20181332T1 (enExample) |
| HU (1) | HUE039450T2 (enExample) |
| IL (1) | IL246823B (enExample) |
| LT (1) | LT3097083T (enExample) |
| MX (1) | MX370546B (enExample) |
| MY (1) | MY180363A (enExample) |
| NZ (1) | NZ723313A (enExample) |
| PH (1) | PH12016501677B1 (enExample) |
| PL (1) | PL3097083T3 (enExample) |
| PT (1) | PT3097083T (enExample) |
| SG (1) | SG11201606971XA (enExample) |
| SI (1) | SI3097083T1 (enExample) |
| TW (1) | TWI689496B (enExample) |
| WO (1) | WO2015110378A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR105400A1 (es) * | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
| EP3484875B1 (en) | 2016-07-14 | 2021-04-07 | Eli Lilly and Company | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| CN108355618B (zh) * | 2018-02-27 | 2020-09-08 | 江南大学 | 牛来源透明质酸酶亲和介质及其吸附方法 |
| CN108776121B (zh) * | 2018-04-08 | 2021-07-30 | 广州卡马生物科技有限公司 | 一种基于荧光猝灭原理对药材中抗氧剂的高通量筛选方法 |
| PE20211644A1 (es) | 2018-09-18 | 2021-08-24 | Terns Inc | Compuestos para tratar ciertas leucemias |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
| CN114671858B (zh) * | 2022-03-07 | 2023-08-08 | 华中师范大学 | 一种苯并咪唑系化合物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| UY34615A (es) | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. |
-
2014
- 2014-01-23 GB GBGB1401086.2A patent/GB201401086D0/en not_active Ceased
-
2015
- 2015-01-19 EP EP18177201.3A patent/EP3395802A1/en not_active Withdrawn
- 2015-01-19 SI SI201530383T patent/SI3097083T1/sl unknown
- 2015-01-19 MX MX2016009442A patent/MX370546B/es active IP Right Grant
- 2015-01-19 NZ NZ72331315A patent/NZ723313A/en not_active IP Right Cessation
- 2015-01-19 EA EA201691468A patent/EA029827B1/ru not_active IP Right Cessation
- 2015-01-19 SG SG11201606971XA patent/SG11201606971XA/en unknown
- 2015-01-19 US US14/599,644 patent/US9440929B2/en active Active
- 2015-01-19 CA CA2941474A patent/CA2941474A1/en not_active Abandoned
- 2015-01-19 BR BR112016016732-5A patent/BR112016016732B1/pt not_active IP Right Cessation
- 2015-01-19 ES ES15701945.6T patent/ES2693019T3/es active Active
- 2015-01-19 JP JP2016548110A patent/JP6472454B2/ja active Active
- 2015-01-19 LT LTEP15701945.6T patent/LT3097083T/lt unknown
- 2015-01-19 PL PL15701945T patent/PL3097083T3/pl unknown
- 2015-01-19 MY MYPI2016702630A patent/MY180363A/en unknown
- 2015-01-19 HR HRP20181332TT patent/HRP20181332T1/hr unknown
- 2015-01-19 EP EP15701945.6A patent/EP3097083B1/en active Active
- 2015-01-19 CN CN201580015662.9A patent/CN106132934B/zh not_active Expired - Fee Related
- 2015-01-19 HU HUE15701945A patent/HUE039450T2/hu unknown
- 2015-01-19 DK DK15701945.6T patent/DK3097083T3/en active
- 2015-01-19 AU AU2015208269A patent/AU2015208269B2/en not_active Ceased
- 2015-01-19 PT PT15701945T patent/PT3097083T/pt unknown
- 2015-01-19 WO PCT/EP2015/050850 patent/WO2015110378A1/en not_active Ceased
- 2015-01-22 AR ARP150100176A patent/AR099160A1/es unknown
- 2015-01-22 TW TW104102159A patent/TWI689496B/zh not_active IP Right Cessation
-
2016
- 2016-07-18 IL IL246823A patent/IL246823B/en active IP Right Grant
- 2016-08-23 PH PH12016501677A patent/PH12016501677B1/en unknown
- 2016-09-12 US US15/262,097 patent/US10179771B2/en active Active
-
2018
- 2018-08-23 US US16/110,353 patent/US20190152922A1/en not_active Abandoned
- 2018-09-11 CY CY181100950T patent/CY1120679T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12065443B2 (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| JP6472454B2 (ja) | 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物 | |
| CN113924146B (zh) | 用于治疗疾病的新化合物及其药物组合物 | |
| KR101676391B1 (ko) | 퇴행성 및 염증성 질병의 치료에 유용한 신규 화합물 | |
| US12264156B2 (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| TWI586352B (zh) | 用於治療發炎之胺基三唑并吡啶及其醫藥組合物 | |
| TW201247202A (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
| JP2017505329A (ja) | 炎症性障害の治療のための新規な塩及びその医薬組成物 | |
| WO2013117649A1 (en) | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases | |
| TW201336844A (zh) | 可用於治療退化及發炎疾病之新穎化合物 | |
| WO2017012647A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| WO2014111380A1 (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
| KR102511209B1 (ko) | 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180112 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181211 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6472454 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |